Economic Dimensions of Personalized and Precision Medicine Pre-Conference
Organized by Ernst R. Berndt, Dana Goldman, and John Rowe
Supported by the University of Southern California
September 21-22, 2016
Columbia University, New York, NY

Wednesday, September 21

1

Predicting Real-World Effectiveness using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework

Darius N. Lakdawalla, University of Southern California and NBER
Jason Shafrin, Precision Health Economics

2

Cost Sharing in Insurance Coverage for Precision Medicine: Preliminary Notes

Mark Pauly, University of Pennsylvania and NBER

3

Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments

Kristopher Hult, University of Chicago

4

Economic Dimensions of Personalized and Precision Medicine in Taiwan and Korea: Evidence from Breast Cancer Treatment

Karen Eggleston, Stanford University and NBER
Rachel Jui-f. Lu, Chang Gung University, Taiwan

5

Rational Integration of Genomic Healthcare Technology: Evidence from PREDICT

John A. Graves, Vanderbilt University
Josh Peterson, Vanderbilt University

6

Empirical Economic Analysis oF Orphan Drug Innovation

Philippe P.E. Gorry, University of Bordeaux